AKBA earnings call for the period ending September 30, 2020.
News & Analysis: Akebia Therapeutics
The company's lead pipeline candidate fell short in a late-stage clinical study.
AKBA earnings call for the period ending March 31, 2020.
The biotech reported great news for its lead pipeline candidate.
Akebia Therapeutics and Satsuma Pharmaceuticals could both be big winners for early shareholders.
The biotech provided a disappointing Q4 update.
AKBA earnings call for the period ending December 31, 2019.
Momentum is continuing for the biotech after an announcement of positive clinical results and buying by key insiders earlier this month.
Insider buying is generating enthusiasm for this biotech stock among investors who aren't insiders.
The biotech's Q3 results weren't anything to crow about. But a big loan agreement will allow Akebia to fund operations until key clinical results are announced.